Last Updated 14 November 2013
Continued growth of Indonesia’s economy and pharmaceutical market
offers revenue-generating opportunities for multinational companies, but it is
clear that successful entry or expansion in this emerging market will depend on
understanding the country’s rapidly evolving healthcare reforms, regulatory
requirements, and political realities. Increasing national investment in the
country’s healthcare and a government commitment to provide universal
healthcare coverage by 2019 will boost demand for healthcare services over the
next five years. Reforms should ultimately provide greater access to medicines
for more Indonesians. However, the government intends to meet the predicted
rise in drug consumption with generic drugs and has implemented various
policies favoring the domestic pharmaceutical industry. Branded drug developers
must also prepare for a new reality of price controls and health technology
Market profile: Market access drivers; key opportunities
and challenges; analysis of more than 40 market parameters.
Economic outlook: Global, regional, and country growth
Socioeconomic trends of 11 Asia-Pacific countries:
Gross domestic product (GDP); nominal per capita gross national income
Demographics of 11 Asia-Pacific countries projected
to 2030: Population size; population growth rate; life expectancy at birth;
median age; percentage of population aged 65 or more; percentage of population
that is urban; tier I and tier II markets based on population; morbidity and
Healthcare investments of 11 Asia-Pacific
countries: Healthcare spending as percentage of GDP (2000-2010); healthcare
spending by government and private entities (2010); healthcare spending per
Pharmaceutical markets (3 regions and 15 countries): Ranking
by size; market sizes; market growth.
Healthcare system: Organization and financing of
public and private sectors; healthcare providers and facilities; health
insurance schemes; healthcare reform plans; national health insurance.
Regulatory affairs: Key decision makers; laws,
regulations, and guidelines; ASEAN regulatory harmonization; local
manufacturing requirements; clinical trials in Indonesia; registration process;
Bolar-type amendment for generics registration.
Pricing and reimbursement: Key decision
makers; public sector tender and procurement; pricing; admission to drug lists
and formularies; health technology assessment.
Cost-containment measures: Generic substitution;
government strategies to promote unbranded generics; generic price-capping;
rational drug use.
Intellectual property protection: Key decision
makers; patent protection; data exclusivity; patent linkage; compulsory
licensing; government-use licensing; counterfeit drugs.
Outlook and implications for the pharmaceutical industry: Key
factors to appreciate when doing business in Indonesia.
Exhibits: 20 data-rich tables and figures.